- Home
- GBLI vs MAZE Comparison
GBLI vs MAZE Comparison
Compare GBLI & MAZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBLI
- MAZE
- Stock Information
- Founded
- GBLI 2016
- MAZE 2018
- Country
- GBLI United States
- MAZE United States
- Employees
- GBLI N/A
- MAZE N/A
- Industry
- GBLI Property-Casualty Insurers
- MAZE
- Sector
- GBLI Finance
- MAZE
- Exchange
- GBLI Nasdaq
- MAZE NYSE
- Market Cap
- GBLI 476.1M
- MAZE 523.1M
- IPO Year
- GBLI 2003
- MAZE 2025
- Fundamental
- Price
- GBLI $31.95
- MAZE $9.12
- Analyst Decision
- GBLI
- MAZE Strong Buy
- Analyst Count
- GBLI 0
- MAZE 3
- Target Price
- GBLI N/A
- MAZE $25.67
- AVG Volume (30 Days)
- GBLI 5.5K
- MAZE 316.7K
- Earning Date
- GBLI 05-07-2025
- MAZE 01-01-0001
- Dividend Yield
- GBLI 4.10%
- MAZE N/A
- EPS Growth
- GBLI 70.49
- MAZE N/A
- EPS
- GBLI 3.12
- MAZE 1.25
- Revenue
- GBLI $441,087,000.00
- MAZE $167,500,000.00
- Revenue This Year
- GBLI $8.70
- MAZE N/A
- Revenue Next Year
- GBLI $14.56
- MAZE N/A
- P/E Ratio
- GBLI $11.03
- MAZE $7.46
- Revenue Growth
- GBLI N/A
- MAZE N/A
- 52 Week Low
- GBLI $29.65
- MAZE $9.30
- 52 Week High
- GBLI $37.00
- MAZE $17.00
- Technical
- Relative Strength Index (RSI)
- GBLI 39.26
- MAZE N/A
- Support Level
- GBLI $34.20
- MAZE N/A
- Resistance Level
- GBLI $34.95
- MAZE N/A
- Average True Range (ATR)
- GBLI 0.63
- MAZE 0.00
- MACD
- GBLI -0.21
- MAZE 0.00
- Stochastic Oscillator
- GBLI 0.00
- MAZE 0.00
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance worldwide. The company's three primary segments are Commercial Specialty, Reinsurance operations, and Exited Lines. The majority of its revenue is from the Commercial Specialty segment. Geographically, the majority is from California.
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.